Virax Biolabs
London
About Virax Biolabs
Virax Biolabs is a biotechnology company focusing on the prevention, detection, and diagnosis of viral diseases. Virax is a revenue-generating group established in 2013 whose primary business is the proprietary development and global distribution of in vitro diagnostic (IVD) test kits. Virax Biolabs is developing an immunology platform based on T-Cell testing. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria & Human Papilloma Virus. Virax Biolabs’ vision is to facilitate the transition into the 'new normal’ during and post-pandemic through the provision of the latest medical equipment and technology. Virax Biolabs is acquiring innovative biosensor technology from which it intends to develop into novel point-of-care biomarker testing devices, that rival lab-based ELISA tests for accuracy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $21.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nasdaq:VRAX
- Website: viraxbiolabs.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Diagnostics, Life Science, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/virax-biolabs-55841 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.